Please login to the form below

Not currently logged in

Novartis submits COPD drug for EU approval

Pharmaceutical company Novartis has submitted an investigational chronic obstructive pulmonary disease therapy for marketing authorisation in the EU following positive phase III trial data

Switzerland-based pharmaceutical company Novartis has submitted an investigational chronic obstructive pulmonary disease (COPD) for marketing authorisation in the EU following a positive phase III trial.

The drug, to be marketed as Seebri Breezhaler (glycopyrronium bromide) if approved, is intended to help people with COPD live more active and productive lives.

The study data supporting the application demonstrated that the drug significantly increased patients' lung function compared to placebo and extended the time before COPD exacerbation – a worsening of the condition's symptoms.

A significant improvement in exercise endurance of COPD patients taking Seebri Breezhaler compared to placebo was also recorded. The number of COPD-related hospitalisations decreased in patients taking the drug was down too.

These data was presented at the European Respiratory Society (ERS) congress in Amsterdam.

Glycopyrronium bromide was licensed to Novartis in April 2005 by Vectura and its development partner Sosei.

27th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....